arrow
T

Tibor Szarvas

Semmelweis University
H指数:35
被引数:3,460

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group

替斯安单抗维多汀在尿路上皮癌患者中的应用:ARON工作组临床试验视角

2026-10-070
PRE
CARDIOLOGIC AND ONCOLOGIC OUTCOMES WITH GLP-1 RECEPTOR AGONISTS IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

在接受雄激素剥夺治疗的前列腺癌患者中,GLP-1受体激动剂的心血管和肿瘤学结局

2026-05-010
PRE
Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses

原发性膀胱和脐尿管腺癌的遗传特征与靶向治疗:一项系统综述及合并描述性基因组学分析

2026-05-010
OAAI
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

更正:比较蛋白质组学和血清分析鉴定了FSCN1作为去势抵抗性前列腺癌中阿比特龙耐药的标志物

2025-12-100
OAAI
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms

都柏林国际泌尿病理学会(ISUP)关于尿囊肿瘤病理学最佳实践建议的共识会议

2025-11-013
PRE
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis

接受恩富妥珠单抗治疗的尿路上皮癌患者的临床与分子预测因子:反应与生存的系统评价和荟萃分析

2025-10-310
OAAI
Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study

多示踪剂比较金标准PSMA-PET/CT与68Ga-FAPI和18F-FDG在高风险前列腺癌中的应用:一项概念验证研究

2025-05-270
PRE
Melanoma Proteomics Unveiled: Harmonizing Diverse Data Sets for Biomarker Discovery and Clinical Insights via MEL-PLOT

黑色素瘤蛋白质组学解析:通过MEL-PLOT协调多样化数据集以发现生物标志物并获得临床洞见

2025-05-051
OA
Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis

雄激素受体通路抑制剂单药治疗在前列腺癌中的应用:安全性、肿瘤学结局及生活质量——一项系统评价和Meta分析

2025-05-010
OAAI
Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis

尿路上皮癌患者接受免疫检查点抑制剂治疗时,治疗前血液炎症生物标志物的预后和预测价值:一项系统评价和荟萃分析

2025-03-170
OA